Still, after a median follow-up of 6.3 years, Randi et al. reported three out of a group of 89 children (3.4%) with ET and JAK2 mutations suffering from major thromboembolic complications, such as cerebral vein thrombosis and Budd-Chiari syndrome [12]. This evidence concerns the gene JAK2 and hepatic veno-occlusive disease.